ReviewFrontiers in microbiology2020
The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses.
Review in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 105 citations in OpenAlex.
- A Novel Cell-Penetrating Lipopeptide for DNA Binding, Self-Assembly, and Delivery Into HeLa and Pluripotent Stem Cells.Journal of peptide science : an official publication of the European Peptide Society · 2026Article
- Trends, Gaps, and Challenges in Antiviral Resistance: A Bibliometric Analysis and Narrative Synthesis of Key Viruses, Resistance Mechanisms, and Drivers.BioMed research international · 2026Article
- Revolution of AAV in Drug Discovery: From Delivery System to Clinical Application.Journal of medical virology · 2025Review
- Review
- Effect of Transmission and Vaccination on Time to Dominance of Emerging Viral Strains: A Simulation-Based Study.Microorganisms · 2023Article
- "Lymphocyte * Neutrophil" count decreased in SARS-CoV-2 Omicron patients in Shanghai with no significant change in CRP and SAA.Journal of clinical laboratory analysis · 2022Article
- Nanoparticles for Coronavirus Control.Nanomaterials (Basel, Switzerland) · 2022Review
- Article
- Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants.JCI insight · 2022Article
- Rapid Degradation of SARS-CoV-2 Spike S Protein by A Specific Serine Protease.Molecules (Basel, Switzerland) · 2022Article
- T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses.Transplant immunology · 2022Review
- BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19.Frontiers in immunology · 2022Article
- DNA Vaccines Expressing the Envelope and Membrane Proteins Provide Partial Protection Against SARS-CoV-2 in Mice.Frontiers in immunology · 2022Article
- The Impact of COVID-19 Pandemic on the Psychological Health and Dental Practice of Oral Healthcare Workers: A Scoping Review.Risk management and healthcare policy · 2022Article
- Article
- Review
- A defective viral genome strategy elicits broad protective immunity against respiratory viruses.Cell · 2021Article
- COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models.Nature communications · 2021Article
- Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies.Journal of medicinal chemistry · 2021Article
- SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review.International journal of biological macromolecules · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Emerging coronaviruses (CoV) are constant global public health threats to society. Multiple ongoing clinical trials for vaccines and antivirals against CoVs showcase the availability of medical interventions to both prevent and treat the future emergence of highly pathogenic CoVs in human. However, given the diverse nature of CoVs and our close interactions with wild, domestic and companion animals, the next epidemic zoonotic CoV could resist the existing vaccines and antivirals developed, which are primarily focused on Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS CoV). In late 2019, the novel CoV (SARS-CoV-2) emerged in Wuhan, China, causing global public health concern. In this review, we will summarize the key advancements of current vaccines and antivirals against SARS-CoV and MERS-CoV as well as discuss the challenge and opportunity in the current SARS-CoV-2 crisis. At the end, we advocate the development of a "plug-and-play" platform technologies that could allow quick manufacturing and administration of broad-spectrum countermeasures in an outbreak setting. We will discuss the potential of AAV-based gene therapy technology for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.